Main Content

Press Releases

2009

Argus 2 edits following press realese about a treatment trial in Manchester: "Bionic eye" trial in Manchester, June  

 

Results from Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors. (Mai 28 2009 - DOC)  

2008

3 million towards gene therapy to treat retinal degenerative diseases (December 10 2008 - DOC)

Second Sight Expands International Clinical Trial for Argus II Retinal Implant [November 19 2008 - DOC]

IAPO launches Patient Safety Toolkit (November 03 2008 - DOC)

Human Neural Stem Cells can prevent vision loss (October 30 2008 - DOC)

People with Recessive Stargardt Disease or Cone-Rod Dystrophy Should Not Exceed the Recommended Daily Allowance for Vitamin A (Oktober 30 2008 - DOC)

Oral retinoid enters trials (October 20 2008 - DOC)

A key mechanism regulating neural stem cell development is uncovered (October 08 2008 - DOC)

Neurotech Granted Fast Track Designations from the FDA for NT-501 in two Indications: Retinitis pigmentosa and Dry Age-Related Macular Degeneration (September 07 2008 - DOC)

Results of world’s first gene therapy for inherited blindness show sight improvement (April 27 2008 - DOC)

Gene Therapy Improves Vision in Patients with Congenital Retinal Disease (April 27 2008 - DOC)  

2007

2006

2005

2004

2002

2001

2000

1999

1998

1997

1996

 


End of article

 

Search

Search

Search

Adapt your Font Size

Font-Size:

Retina International Statement

Retina International Is Seeking A Cure For
Retinitis Pigmentosa (RP), Macular Degeneration, Usher Syndrome and Allied Retinal Dystrophies